Archive for the ‘Lpath Inc’ Category

Lpath Inc

May 8th, 2014 | Posted in 2014, Lpath Inc

Lpath, Inc., San Diego, announced that it has been awarded a $1,7 Million, from the National Institutes of Neurological Diseases and Stroke, to develop its antibody therapeutic, Lpathomab.  

Lpath Inc.

December 5th, 2013 | Posted in 2013, Lpath Inc

Lpath Inc. – Is an antibody developer that has recently announced its new antibody program targeting respiratory disease, called Altepan.  Using its proprietary drug-discovery technology, ImmuneY2, the company said it has generated several monoclonal antibody product candidates targeting leukotrine family of bioacative lipids, which are implicated in numerous inflammatory processes.  Lpath will look to file […]

Lpath Inc

February 10th, 2011 | Posted in 2011, Lpath Inc

Lpath Inc., has received official notification from the U.S. Patent and Trademark Office and the European Patent Office (EPO) that Lpath was issued two key patents related to Asonep, one of the company’s two lead drug candidates that will be studied in Phase 2 trials throughout next year.

Lpath Inc

December 27th, 2010 | Posted in 2011, Lpath Inc

Lpath Inc., San Diego, has entered into an agreement providing Pfizer with an exclusive option for a global worldwide license to develop and commercialize iSONEP, Lpath’s lead monoclonal antibody product candidate that is being evaluated for the treatment of wet age-related macular degeneration (wetADM) and other opthalmology disorders. Under the term sof the agreement, Pfizer […]